Literature DB >> 12951703

[Renal cell carcinoma in adults less than 40 years of age: a particular cancer? Incidence, outcome and review of the literature].

A Rodriguez1, H Tazi, J J Patard, B Lobel.   

Abstract

OBJECTIVE: To study the incidence, clinical presentation, pathological prognostic factors and disease outcome of RCC in young adults less than 40-years-old.
MATERIAL AND METHODS: The notes of 400 patients treated by radical nephrectomy for RCC suspicion, between January 1984 and december 1999 were reviewed. Twenty-nine patients (7.25%) were under 40.
RESULTS: The most common histological cell type was clear cell carcinoma, found in 20 patients (69%). At a median follow-up of 80 months, 20 patients (69%) were disease free and 9 (31%) died of the disease. When comparing patients less than 40 years vs older than 40 years, we found significant differences in histology type (clear cell carcinoma 69% vs 91%; P = 0.0001), and tumor stage at presentation (pT2 = 34.5% vs 17.3%; P = 0.04) (pT3 = 20.7% vs. 42%; P = 0.03). Disease free survival was not significantly different between the 2 groups (69% vs 65.7%; Log rank test P = 0.4).
CONCLUSION: Although rare, RCC in young adults seems to follow a course similar to the disease seen in older patients. Stage at presentation was different between the 2 populations however survival was not affected by age.

Entities:  

Mesh:

Year:  2003        PMID: 12951703     DOI: 10.1016/s0003-4401(03)00055-x

Source DB:  PubMed          Journal:  Ann Urol (Paris)        ISSN: 0003-4401


  1 in total

1.  Age at diagnosis is a determinant factor of renal cell carcinoma-specific survival in patients treated with nephrectomy.

Authors:  Pierre I Karakiewicz; Claudio Jeldres; Nazareno Suardi; George C Hutterer; Paul Perrotte; Umberto Capitanio; Vincenzo Ficarra; Luca Cindolo; Alexandre de La Taille; Jacques Tostain; Peter F Mulders; Laurent Salomon; Richard Zigeuner; Luigi Schips; Denis Chautard; Antoine Valeri; Eric Lechevallier; Jean-Luc Descots; Herve Lang; Arnaud Mejean; Gregory Verhoest; Jean-Jacques Patard
Journal:  Can Urol Assoc J       Date:  2008-12       Impact factor: 1.862

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.